- AVITA Medical press release ( NASDAQ: RCEL ): Q2 GAAP EPS of -$0.25 beats by $0.15 .
- Revenue of $8.34M (-19.0% Y/Y) beats by $1.18M .
- Shares +1.4% .
- Reported total revenue, which includes BARDA revenue, of $8.3 million compared to $10.3 million in the corresponding period in the prior year, which included $3.6 million in BARDA revenue
- Commercial revenues in calendar year 2022 are projected to be approximately $30 million, excluding BARDA revenues, which represents a 20% increase year-over year. We project BARDA revenues of approximately $0.3 million in calendar year 2022, as compared to $7.9 million in calendar year 2021, since we completed delivery of RECELL units into the national stockpile in 2021.
For further details see:
AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M